- Home
- YJ vs QNRX Comparison
YJ vs QNRX Comparison
Compare YJ & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YJ | QNRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.2M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | YJ | QNRX |
|---|---|---|
| Price | $1.25 | $4.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 29.9K |
| Earning Date | 03-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $3.25 |
| 52 Week High | $2.67 | $41.80 |
Technical Indicators
Market Signals| Indicator | YJ | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 44.83 |
| Support Level | $1.26 | $4.09 |
| Resistance Level | $1.62 | $5.11 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 3.54 | 29.85 |
Price Performance
Historical ComparisonAbout YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.